부산대학교 도서관

Introduction: This study examined real-world data from patients who received eribulin for metastatic breast cancer (MBC) collected from 14 hospitals across the UK. Methods: Anonymized data were collected retrospectively from patients with MBC who had received eribulin. The data included the hormone-receptor status, histological diagnosis, age, prior chemotherapy, response to eribulin, progression-free survival (PFS), and overall survival (OS). Results: Among 577 patients analyzed, the median age was 56 years, and most patients (73%) were estrogen-receptor positive. The median OS was 288 days (95% confidence interval [CI]: 261-315), and the PFS was 117 days (95% CI: 105-129). The median OS was higher among older patients ([GreaterEqual]65 vs. 2 prior: 328 days [95% CI: 264-385] vs. 264 days [95% CI: 229-298]; p = 0.042). Discussion/Conclusion: These retrospective data suggest that eribulin can be successfully used in older patients with MBC. Eribulin treatment was more effective in earlier-line settings, which, while predictable, supports consideration of eribulin as a second-line treatment option. Keywords: Metastatic breast cancer, Older adults, Second-line treatment, Eribulin, Observation study, Real-world data
Author(s): Mariam Jafri [a]; Hartmut Kristeleit [b]; Vivek Misra [c]; Mark Baxter [d]; Samreen Ahmed [e]; Apurna Jegannathen [f]; Ankit Jain [g]; David Maskell [h]; Urmila Barthakur [i]; Gwenllian Edwards [...]